top of page

Eyes on Pharma
Check-out What Intel Caught our Eye


Recent M&A Activities
We're still tracking some of the ways firms are working to optimize their portfolios and managing competitive strategy. This week we're looking at two M&A deals: Ono Pharma's agreement with Biohaven for IgG degraders and Gilead's deal with Vir Bio for T-cell engagers. For the regional rights to three of Biohaven’s IgG degraders, including a phase 3-stage Grave’s disease potential, Japan’s Ono Pharmaceutical is paying $80 million up front. Ono also agreed to a $20 million mi

Jana Chisholm
Nov 95 min read


EyesOn Clinical Updates
We've recently had EyesOn some of the Clinical data being released. Today we catch up with the details from Argenx, Zealand Pharma, and AbbVie data readouts.

Jana Chisholm
Nov 26 min read


Executing the Strategic Plan
This week EyesOn Pharma is highlighting some recent business deals that are helping BioPharma firms execute their Strategic Plans. See more on Roche's manufacturing improvements, Earendil Labs' deal to further their antibody production, and Novo's cardiometabolic product line-extension deal.

Jana Chisholm
Oct 265 min read


Clinical Trial Updates
With blockbuster sales of Caplyta, Johnson & Johnson’s $14.6 billion investment in Intra-Cellular Therapies continues to pay off.

Jana Chisholm
Oct 105 min read


EyesOn BioPharma Business Development Activities
BioPharma dealmaking is still going strong this summer. We're highlighting a few companies that caught our EyesOn team attention. Check out details on the Roche + Hanmi, Leo Pharma + Tanabe, and the SK BioPharma + Biohaven deals. By paying $190 million up front for a clinical-stage UCN2 (urocortin-2) analogue from South Korea’s Hanmi Pharm, Roche has advanced its obesity approach into unprecedented territory. Eli Lilly investigated the mechanism in a heart failure medicatio

Jana Chisholm
Sep 186 min read


EyesOn Clinical Assets
We still have EyesOn Clinical Asset updates. This week we cover GSK's FDA approval for Jideytro, Royalty's ATTR deal, plus the Sanofi and Roche portfolio adjustments that include discontinuation of some assets.

Jana Chisholm
Sep 410 min read


Corporate Strategy Updates -BioNTech, Pfizer, and Astra Zeneca+BMS
We've been keeping EyesOn Strategic moves in the BioPharma space. Today we look at BioNTech's new CEO, Pfizer's continuing restructuring moves to remain competitive, and the reactions to a potential BMS + AZN merger.

Jana Chisholm
Aug 286 min read


Recent Clinical Updates: Otsuka & Sanofi
We've had EyesOn recent clinical trial updates. Otsuka Pharma received approval for their ADHD therapy, Simtriyo, potentially a game changer for patients aged 6 and older. Meanwhile, Sanofi has stopped development of SAR445399, in bronchiectasis patients without cystic fibrosis as part of ther Portfolio re-alignment efforts.

Jana Chisholm
Aug 224 min read


EyesOn Industry News - Sanofi & Merck KGaA
This week we had EyesOn Merck KGaA and Sanofi and their corporate activities. Read about the antitrust proceedings against Sanofi and their Flu vaccine, and how the new CEO of Merck is changing their strategic direction with M&A.

Jana Chisholm
Aug 75 min read


EyesOn Orca, Vertex, & Ipsen Clinical Data
This week we've had EyesOn clinical data and approvals for therapies in hematology and neurology. Check out the news onVertex's gene therapy approval for patients as young as 2-years old, Orca's allogeneic cell therapies approval for GVHD, and Ipsen's neurotoxin Phase 3 data showing efficacy in both episodic and chronic migraines.

Jana Chisholm
Jul 317 min read


EyesOn The Competitive Edge
This week we're sharing a couple of articles focused on competitive advantage in US BioPharma. Take a look at how the Oral GLP-1 market is shaping up, and the new US Initiative Operation TrialBlazer is trying to boost US Early-Stage Clinical Development Capabilities.

Jana Chisholm
Jul 244 min read


EyesOn AbbVie, Sangamo, and Pfizer
This week we've had EyesOn all the recent Business Development activities in the BioPharma world. We're sharing a few that caught our eye. Check out AbbVie's acquisition of Apogee to strengthen out their I&I portfolio, Sangamo's asset sale, and Pfizer's recent clinical results from one of their Seagen candidates.

Jana Chisholm
Jul 175 min read


EyesOn Risk Management In Action
Although GSK and Takeda are facing very different circumstances, both companies are flexing their Risk management skills to remain competitive.

Jana Chisholm
Jul 63 min read


EyesOn Oncology Clinical Data
Three recent clinical updates illustrate the opportunities and challenges facing next-generation oncology therapies. ADC Therapeutics reported positive efficacy data for Zynlonta...

Jana Chisholm
Jul 13 min read


EyesOn Strategic Agility
EyesOn Strategic Agility in Action: How Biopharma Companies Are Managing Clinical, Commercial, and Operational Levers to Sustain Growth

Jana Chisholm
Jun 217 min read


EyesOn Leveraging Clinical Results
Clinical Data Drives Strategic Decisions: Oruka, Boehringer, and Astellas Navigate Risk and Opportunity. Recent trial readouts highlight how clinical outcomes—positive and negative—are shaping portfolio decisions and competitive positioning.

Jana Chisholm
May 312 min read


EyesOn Strategic Growth via M&A
From biosimilars scale to targeted oncology innovation, recent deals highlight how companies are using acquisition to accelerate positioning across key therapeutic and market opportunities.

Jana Chisholm
May 193 min read


EyesOn ADC's
ADC Arms Race Accelerates: Lilly and Gilead Double Down on Next-Generation Oncology Platforms. Acquisitions of CrossBridge and Tubulis highlight how antibody-drug conjugates are becoming a central pillar of oncology pipeline strategy.

Jana Chisholm
May 143 min read


EyesOn Competitive Strategy
Strategic Reallocation in Action: Takeda, Daiichi Sankyo, and Shionogi refocus for Growth and Market Access. Portfolio exits, capital shifts, and U.S. manufacturing expansion highlight how companies are actively adjusting strategic levers.

Jana Chisholm
May 43 min read


Launch Momentum Meets Market Reality: Managing the Levers for Success
Strong clinical performance remains essential—but sustained commercial success increasingly depends on how effectively companies align pricing, access, targeting, and competitive positioning

Jana Chisholm
Apr 304 min read
bottom of page
.png)